MARC details
| 000 -LEADER |
|---|
| fixed length control field |
03189cam a2200421Mi 4500 |
| 001 - CONTROL NUMBER |
|---|
| control field |
on1314619846 |
| 003 - CONTROL NUMBER IDENTIFIER |
|---|
| control field |
OCoLC |
| 005 - DATE AND TIME OF LATEST TRANSACTION |
|---|
| control field |
20240726104850.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION |
|---|
| fixed length control field |
220507s2022 si o ||| 0 eng d |
| 040 ## - CATALOGING SOURCE |
|---|
| Original cataloging agency |
EBLCP |
| Language of cataloging |
eng |
| Description conventions |
rda |
| Transcribing agency |
EBLCP |
| Modifying agency |
DXU |
| -- |
NT |
| 066 ## - CHARACTER SETS PRESENT |
|---|
| Alternate G0 or G1 character set |
(S |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9789815039740 |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER |
|---|
| International Standard Book Number |
9815039741 |
| 050 04 - LIBRARY OF CONGRESS CALL NUMBER |
|---|
| Classification number |
RC280 |
| Item number |
.N366 2022 |
| 049 ## - LOCAL HOLDINGS (OCLC) |
|---|
| Holding library |
MAIN |
| 100 1# - MAIN ENTRY--PERSONAL NAME |
|---|
| Personal name |
Mukherjee, Biswajit. |
| Relator term |
Author |
| 245 10 - TITLE STATEMENT |
|---|
| Title |
Nanotherapeutics for the Treatment of Hepatocellular Carcinoma |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. |
|---|
| Place of publication, distribution, etc. |
Singapore : |
| Name of publisher, distributor, etc. |
Bentham Science Publishers, |
| Date of publication, distribution, etc. |
(c)2022. |
| 300 ## - PHYSICAL DESCRIPTION |
|---|
| Extent |
1 online resource (557 pages) |
| 336 ## - CONTENT TYPE |
|---|
| Content type term |
text |
| Content type code |
txt |
| Source |
rdacontent |
| 337 ## - MEDIA TYPE |
|---|
| Media type term |
computer |
| Media type code |
c |
| Source |
rdamedia |
| 338 ## - CARRIER TYPE |
|---|
| Carrier type term |
online resource |
| Carrier type code |
cr |
| Source |
rdacarrier |
| 347 ## - DIGITAL FILE CHARACTERISTICS |
|---|
| File type |
data file |
| Source |
rda |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Description based upon print version of record. |
| 504 ## - BIBLIOGRAPHY, ETC. NOTE |
|---|
| Bibliography, etc. note |
Includes bibliographies and index. |
| 505 00 - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Cover -- |
| Title |
Title -- |
| -- |
Copyright -- |
| -- |
End User License Agreement -- |
| -- |
Contents -- |
| -- |
Preface -- |
| -- |
List of Contributors -- |
| -- |
Hepatocellular Carcinoma: Diagnosis, Molecular Pathogenesis, Biomarkers, and Conventional Therapy -- |
| -- |
Biswajit Mukherjee*, 1, Manasadeepa Rajagopalan2, Samrat Chakraborty1, Prasanta Ghosh1, Manisheeta Ray1, Ramkrishna Sen1 and Iman Ehsan1 -- |
| -- |
INTRODUCTION -- |
| -- |
CANCER AND ITS TYPES -- |
| -- |
Primary Liver Cancer -- |
| -- |
Hepatocellular Carcinoma (HCC) -- |
| -- |
Intrahepatic Cholangiocarcinoma (Bile Duct Cancer) -- |
| -- |
Angiosarcoma and Hemangiosarcoma -- |
| -- |
Hepatoblastoma -- |
| -- |
Secondary Liver Cancer |
| 505 00 - FORMATTED CONTENTS NOTE |
|---|
| Formatted contents note |
Surgical Resection in Advanced HCC -- |
| Title |
Anatomical Resection -- |
| -- |
Laparoscopic Resection of The Liver -- |
| -- |
Surgical Resection of Re-Occurring HCC -- |
| -- |
Liver Transplantation -- |
| -- |
Ablation -- |
| -- |
Palliative Treatment -- |
| -- |
Embolizing Therapies for HCC -- |
| -- |
Transarterial Chemoembolization (TACE) -- |
| -- |
Radiotherapy -- |
| -- |
Systemic Therapies of HCC -- |
| -- |
First-line Therapy -- |
| -- |
Second-line Therapy -- |
| -- |
Multi-Target Tyrosine Kinase Inhibitors -- |
| -- |
Immune Checkpoint Inhibitor -- |
| -- |
FUTURE PERSPECTIVES -- |
| -- |
CONCLUSIONS -- |
| -- |
CONSENT FOR PUBLICATION -- |
| -- |
CONFLICT OF INTEREST -- |
| -- |
ACKNOWLEDGEMENT -- |
| -- |
REFERENCES |
| 500 ## - GENERAL NOTE |
|---|
| General note |
Hepatocellular Carcinoma and Therapeutic Challenges. |
| 520 0# - SUMMARY, ETC. |
|---|
| Summary, etc. |
Hepatocellular carcinoma (HCC) is a leading cause of death globally. Conventional chemotherapeutic agents are unable to penetrate cancerous hepatocytes completely and are toxic to non cancerous cells and tissues. This toxicity significantly compromises the therapeutic outcome of conventional chemotherapeutic agents which is also reflected in the high mortality of the disease. Nanotherapeutics have shed new light onto HCC treatment by enabling site-specific in vivo delivery of chemotherapeutics specifically to neoplastic hepatocytes without affecting normal hepatocytes. Thus, nanotherapeutics h. |
| 530 ## - COPYRIGHT INFORMATION: |
|---|
| COPYRIGHT INFORMATION |
COPYRIGHT NOT covered - Click this link to request copyright permission: |
| Uniform Resource Identifier |
<a href="b">b</a> |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Liver |
| General subdivision |
Cancer |
| -- |
Treatment. |
| 650 #0 - SUBJECT ADDED ENTRY--TOPICAL TERM |
|---|
| Topical term or geographic name entry element |
Nanomedicine. |
| 655 #1 - INDEX TERM--GENRE/FORM |
|---|
| Genre/form data or focus term |
Electronic Books. |
| 856 40 - ELECTRONIC LOCATION AND ACCESS |
|---|
| -- |
Click to access digital title | log in using your CIU ID number and my.ciu.edu password. |
| Uniform Resource Identifier |
<a href="httpss://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3199725&site=eds-live&custid=s3260518">httpss://search.ebscohost.com/login.aspx?direct=true&scope=site&db=nlebk&db=nlabk&AN=3199725&site=eds-live&custid=s3260518</a> |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) |
|---|
| Koha item type |
Online Book (LOGIN USING YOUR MY CIU LOGIN AND PASSWORD) |
| DONATED BY: |
|
| VENDOR |
EBSCO |
| Classification part |
RC. |
| PUBLICATION YEAR |
2022 |
| LOCATION |
ONLINE |
| REQUESTED BY: |
|
| -- |
|
| -- |
NFIC |
| Source of classification or shelving scheme |
|
| 994 ## - |
|---|
| -- |
92 |
| -- |
NT |
| 902 ## - LOCAL DATA ELEMENT B, LDB (RLIN) |
|---|
| a |
1 |
| b |
Cynthia Snell |
| c |
1 |
| d |
Cynthia Snell |